Gain Therapeutics (GANX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$8.8 million.
- Gain Therapeutics' Enterprise Value rose 2690.7% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.8 million, marking a year-over-year increase of 2690.7%. This contributed to the annual value of -$10.4 million for FY2024, which is 3815.97% up from last year.
- Gain Therapeutics' Enterprise Value amounted to -$8.8 million in Q3 2025, which was up 2690.7% from -$6.7 million recorded in Q2 2025.
- Gain Therapeutics' 5-year Enterprise Value high stood at -$6.7 million for Q2 2025, and its period low was -$46.6 million during Q1 2021.
- Over the past 5 years, Gain Therapeutics' median Enterprise Value value was -$16.9 million (recorded in 2024), while the average stood at -$21.5 million.
- In the last 5 years, Gain Therapeutics' Enterprise Value tumbled by 39146.18% in 2021 and then surged by 6044.0% in 2025.
- Quarter analysis of 5 years shows Gain Therapeutics' Enterprise Value stood at -$36.9 million in 2021, then surged by 45.4% to -$20.1 million in 2022, then grew by 16.6% to -$16.8 million in 2023, then skyrocketed by 38.16% to -$10.4 million in 2024, then rose by 15.2% to -$8.8 million in 2025.
- Its Enterprise Value stands at -$8.8 million for Q3 2025, versus -$6.7 million for Q2 2025 and -$9.1 million for Q1 2025.